Sonoma Pharmaceuticals, Inc. (SNOA)
1.17
-0.05
(-4.10%)
USD |
NASDAQ |
Oct 08, 15:41
Sonoma Pharmaceuticals Gross Profit Margin (Quarterly) : 40.23% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.23% |
| March 31, 2026 | 39.22% |
| December 31, 2025 | 37.94% |
| September 30, 2025 | 37.83% |
| June 30, 2025 | 36.46% |
| March 31, 2025 | 40.70% |
| December 31, 2024 | 35.63% |
| September 30, 2024 | 38.03% |
| June 30, 2024 | 38.51% |
| March 31, 2024 | 31.72% |
| December 31, 2023 | 46.53% |
| September 30, 2023 | 36.25% |
| June 30, 2023 | 35.13% |
| March 31, 2023 | 28.67% |
| December 31, 2022 | 28.23% |
| September 30, 2022 | 40.11% |
| June 30, 2022 | 36.30% |
| March 31, 2022 | 4.18% |
| December 31, 2021 | 41.45% |
| September 30, 2021 | 33.15% |
| June 30, 2021 | 39.44% |
| March 31, 2021 | -8.99% |
| December 31, 2020 | 40.42% |
| September 30, 2020 | 43.37% |
| June 30, 2020 | 39.10% |
| Date | Value |
|---|---|
| March 31, 2020 | 38.33% |
| December 31, 2019 | 45.53% |
| September 30, 2019 | 46.01% |
| June 30, 2019 | 51.01% |
| March 31, 2019 | 42.79% |
| December 31, 2018 | 53.92% |
| September 30, 2018 | 49.14% |
| June 30, 2018 | 39.62% |
| March 31, 2018 | 36.44% |
| December 31, 2017 | 48.90% |
| September 30, 2017 | 42.73% |
| June 30, 2017 | 45.95% |
| March 31, 2017 | 48.32% |
| December 31, 2016 | 50.76% |
| September 30, 2016 | 37.03% |
| June 30, 2016 | 37.19% |
| March 31, 2016 | 48.92% |
| December 31, 2015 | 39.79% |
| September 30, 2015 | 51.55% |
| June 30, 2015 | 50.90% |
| March 31, 2015 | 50.10% |
| December 31, 2014 | 51.46% |
| September 30, 2014 | 53.06% |
| June 30, 2014 | 56.19% |
| March 31, 2014 | 47.46% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -54.00% |
| Return on Assets | -15.25% |
| Return on Invested Capital | -46.37% |
| Profit Margin (Quarterly) | -5.15% |
| Operating Margin (Quarterly) | -0.62% |
| Return on Net Operating Assets | -28.63% |